LEE011 |
|||
| A8641-5 | ApexBio | 5 mg | EUR 64 |
|
Description: CDK4/6 inhibitor |
|||
LEE011 |
|||
| A8641-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 70 |
|
Description: CDK4/6 inhibitor |
|||
LEE011 |
|||
| A8641-50 | ApexBio | 50 mg | EUR 200 |
|
Description: CDK4/6 inhibitor |
|||
Lee011 |
|||
| 20-abx182504 | Abbexa |
|
|
LEE011 |
|||
| GW0606-1 | Glentham Life Sciences | 1 | EUR 121.8 |
LEE011 |
|||
| GW0606-10 | Glentham Life Sciences | 10 | EUR 237.4 |
LEE011 |
|||
| GW0606-5 | Glentham Life Sciences | 5 | EUR 171.5 |
LEE011 succinate |
|||
| B1084-10 | ApexBio | 10 mg | EUR 101 |
|
Description: CDK inhibitor |
|||
LEE011 succinate |
|||
| B1084-100 | ApexBio | 100 mg | EUR 420 |
|
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|||
LEE011 succinate |
|||
| B1084-200 | ApexBio | 200 mg | EUR 640.8 |
|
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|||
LEE011 succinate |
|||
| B1084-25 | ApexBio | 25mg | EUR 160 |
|
Description: CDK inhibitor |
|||
LEE011 succinate |
|||
| B1084-5 | ApexBio | 5 mg | EUR 60 |
|
Description: CDK inhibitor |
|||
LEE011 succinate |
|||
| B1084-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 192 |
|
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|||
LEE011 succinate |
|||
| B1084-50 | ApexBio | 50 mg | EUR 200 |
|
Description: CDK inhibitor |
|||
LEE011 succinate |
|||
| B1084-500 | ApexBio | 500 mg | EUR 1101.6 |
|
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
|||